GNPTG

Across TCGA pan-cancer cohorts, GNPTG mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GNPTG data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GNPTG mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GNPTG expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where GNPTG mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.459	0.864	.005	34	view →
LUAD	DFS	Quartile	All	0.800	0.990	.011	27	view →
CCRCC	DFS	Tertile	III,IV	0.306	0.708	.003	18	view →
UCEC	OS	Tertile	All	0.875	0.973	.039	6	view →
GBM	DFS	Tertile	All	0.439	0.281	.036	4	view →
HNSC	DFS	Median	All	0.920	0.981	.030	2	view →
LSCC	DFS	Median	III,IV	0.988	0.643	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GNPTG–PDAC (DFS)

Open the PDAC breakdown →